Bausch & Lomb (TSX:BLCO) FCF Margin % : -5.88% (As of Dec. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Bausch & Lomb FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Bausch & Lomb's Free Cash Flow for the three months ended in Dec. 2023 was C$-93 Mil. Bausch & Lomb's Revenue for the three months ended in Dec. 2023 was C$1,574 Mil. Therefore, Bausch & Lomb's FCF Margin % for the quarter that ended in Dec. 2023 was -5.88%.

As of today, Bausch & Lomb's current FCF Yield % is -3.77%.

The historical rank and industry rank for Bausch & Lomb's FCF Margin % or its related term are showing as below:

TSX:BLCO' s FCF Margin % Range Over the Past 10 Years
Min: -4.78 Med: 12.05 Max: 18.06
Current: -4.78

During the past 6 years, the highest FCF Margin % of Bausch & Lomb was 18.06%. The lowest was -4.78%. And the median was 12.05%.

TSX:BLCO's FCF Margin % is ranked better than
53.16% of 824 companies
in the Medical Devices & Instruments industry
Industry Median: -7.14 vs TSX:BLCO: -4.78

Bausch & Lomb FCF Margin % Historical Data

The historical data trend for Bausch & Lomb's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch & Lomb FCF Margin % Chart

Bausch & Lomb Annual Data

Trend

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

16.38

7.71

18.06

4.51

-4.78

Bausch & Lomb Quarterly Data
	Dec18	Dec19	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Margin %	Get a 7-Day Free Trial											10.94	-9.99	-5.22	1.79	-5.88

Competitive Comparison of Bausch & Lomb's FCF Margin %

For the Medical Instruments & Supplies subindustry, Bausch & Lomb's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bausch & Lomb's FCF Margin % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Bausch & Lomb's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Bausch & Lomb's FCF Margin % falls into.

Bausch & Lomb FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Bausch & Lomb's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-265.637	/	5562.274
	=	-4.78 %

Bausch & Lomb's FCF Margin for the quarter that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	-92.57	/	1573.697
	=	-5.88 %

Bausch & Lomb FCF Margin % Related Terms

Thank you for viewing the detailed overview of Bausch & Lomb's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Bausch & Lomb (TSX:BLCO) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bausch & Lomb Corp (TSX:BLCO) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

BLCO:USA S2L:Germany

Address

520 Applewood Crescent, Vaughan, ON, CAN, L4K 4B4

Website

https://www.bausch.com

Bausch & Lomb is one of the largest vision care companies in the U.S. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market which B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.